PIPAC is a new and promising technique for the intraperitoneal administration of chemotherapy. It can be used in patients with various peritoneal cancer metastases. It is mainly a palliative treatment, but there is some neoadjuvant treatment potential. We have operated on 41 patients with various intra-abdominal cancers. PIPAC was performed every 6 weeks. The indication was extension of peritoneal carcinomatosis beyond the criteria for cytoreductive surgery and HIPEC. The effect was evaluated according to the peritoneal cancer index, the peritoneal regression grading score and the amount of ascites. Complications were classified according to the Clavien-Dindo system. We have performed 100 PIPAC procedures. There were two major complications, classified as Clavien Dindo III (2%). The number of procedures varied from 1 to 6. Five patients switched to cytoreductive surgery and HIPEC, and one was indicated for the watch and wait strategy due to total regression according to PRGS. Three patients are still continuing treatment. The others stopped treatment mainly because of progression of the disease and loss of metastases. We observed a reduction in ascites production soon after PIPAC application. PIPAC is a safe and well-tolerated treatment modality. It is mainly a palliative treatment that can improve the quality of life by reducing the production of ascites, but in about 10% of cases, it can reduce the extent of the disease and allow for further radical treatment.

1st Department of Surgery General University Hospital 128 08 Prague Czech Republic

1st Medical Faculty Charles University 120 00 Prague Czech Republic

Department of Oncology General University Hospital 128 08 Prague Czech Republic

See more in PubMed

Hoskovec D., Krška Z., Vočka M., Dytrych P. PIPAC—Overview of the Method and First Use in the Czech Republic. Rozhl. Chir. 2020;99:529–533. PubMed

Guel-Klein S., Alberto Vilchez M.E., Ceelen W., Rau B., Brandl A. Is PIPAC a Treatment Option in Upper and Lower Gastrointestinal Cancer with Peritoneal Metastasis? Visc. Med. 2022;38:90–98. doi: 10.1159/000523901. PubMed DOI PMC

Li Z., Wong L.C.K., Sultana R., Lim H.J., Tan J.W.-S., Tan Q.X., Wong J.S.M., Chia C.S., Ong C.-A.J. A Systematic Review on Quality of Life (QoL) of Patients with Peritoneal Metastasis (PM) Who Underwent Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Pleura Peritoneum. 2022;7:39–49. doi: 10.1515/pp-2021-0154. PubMed DOI PMC

Solass W., Kerb R., Mürdter T., Giger-Pabst U., Strumberg D., Tempfer C., Zieren J., Schwab M., Reymond M.A. Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy. Ann. Surg. Oncol. 2014;21:553–559. doi: 10.1245/s10434-013-3213-1. PubMed DOI PMC

Van Der Speeten K., Kilian M., Lemione L. Application of IPC, HIPEC, and PIPAC. In: Rau B., Königsrainer A., Mohamed F., Sugarbaker P.H., editors. Peritoneal Tumors and Metastases. Springer International Publishing; Cham, Switzerland: 2021. pp. 111–133.

Račkauskas R., Baušys A., Lukšta M., Jurgaitis J., Paškonis M., Strupas K. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) for Peritoneal Malignancy: Initial Experience of the First Program in the Baltic Countries. World J. Surg. Oncol. 2021;19:236. doi: 10.1186/s12957-021-02357-5. PubMed DOI PMC

Di Giorgio A., Macrì A., Ferracci F., Robella M., Visaloco M., De Manzoni G., Sammartino P., Sommariva A., Biacchi D., Roviello F., et al. 10 Years of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): A Systematic Review and Meta-Analysis. Cancers. 2023;15:1125. doi: 10.3390/cancers15041125. PubMed DOI PMC

Nadiradze G., Horvath P., Sautkin Y., Archid R., Weinreich F.-J., Königsrainer A., Reymond M.A. Overcoming Drug Resistance by Taking Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Cancers. 2019;12:34. doi: 10.3390/cancers12010034. PubMed DOI PMC

Ndaw S., Hanser O., Kenepekian V., Vidal M., Melczer M., Remy A., Robert A., Bakrin N. Occupational Exposure to Platinum Drugs during Intraperitoneal Chemotherapy. Biomonitoring and Surface Contamination. Toxicol. Lett. 2018;298:171–176. doi: 10.1016/j.toxlet.2018.05.031. PubMed DOI

Willaert W., Sessink P., Ceelen W. Occupational Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Pleura Peritoneum. 2017;2:121–128. doi: 10.1515/pp-2017-0018. PubMed DOI PMC

Katdare N., Prabhu R., Mishra S., Mehta S., Bhatt A. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Initial Experience from Indian Centers and a Review of Literature. Indian. J. Surg. Oncol. 2019;10:24–30. doi: 10.1007/s13193-018-0771-5. PubMed DOI PMC

Sgarbura O., Villeneuve L., Alyami M., Bakrin N., Torrent J.J., Eveno C., Hübner M., Abba J., Afifi A., Mortensen M.B., et al. Current Practice of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Still Standardized or on the Verge of Diversification? Eur. J. Surg. Oncol. 2021;47:149–156. doi: 10.1016/j.ejso.2020.08.020. PubMed DOI

Alyami M., Hübner M., Grass F., Bakrin N., Villeneuve L., Laplace N., Passot G., Glehen O., Kepenekian V. Pressurised Intraperitoneal Aerosol Chemotherapy: Rationale, Evidence, and Potential Indications. Lancet Oncol. 2019;20:e368–e377. doi: 10.1016/S1470-2045(19)30318-3. PubMed DOI

Guchelaar N.A.D., Noordman B.J., Koolen S.L.W., Mostert B., Madsen E.V.E., Burger J.W.A., Brandt-Kerkhof A.R.M., Creemers G.-J., De Hingh I.H.J.T., Luyer M., et al. Intraperitoneal Chemotherapy for Unresectable Peritoneal Surface Malignancies. Drugs. 2023;83:159–180. doi: 10.1007/s40265-022-01828-7. PubMed DOI PMC

Mariano G., Pocard M., Eveno C. PIPAC: 8 Key Points for a Good Practice with Video. J. Visc. Surg. 2019;156:169–171. doi: 10.1016/j.jviscsurg.2019.01.006. PubMed DOI

Verwaal V.J., Van Tinteren H., Van Ruth S., Zoetmulder F.A.N. Predicting the Survival of Patients with Peritoneal Carcinomatosis of Colorectal Origin Treated by Aggressive Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. Br. J. Surg. 2004;91:739–746. doi: 10.1002/bjs.4516. PubMed DOI

Solass W., Sempoux C., Detlefsen S., Carr N.J., Bibeau F. Peritoneal Sampling and Histological Assessment of Therapeutic Response in Peritoneal Metastasis: Proposal of the Peritoneal Regression Grading Score (PRGS) Pleura Peritoneum. 2016;1:99–107. doi: 10.1515/pp-2016-0011. PubMed DOI PMC

Dindo D., Demartines N., Clavien P.-A. Classification of Surgical Complications: A New Proposal with Evaluation in a Cohort of 6336 Patients and Results of a Survey. Ann. Surg. 2004;240:205–213. doi: 10.1097/01.sla.0000133083.54934.ae. PubMed DOI PMC

Alyami M., Mercier F., Siebert M., Bonnot P.-E., Laplace N., Villeneuve L., Passot G., Glehen O., Bakrin N., Kepenekian V. Unresectable Peritoneal Metastasis Treated by Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Leading to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Eur. J. Surg. Oncol. 2021;47:128–133. doi: 10.1016/j.ejso.2019.06.028. PubMed DOI

Sgarbura O., Eveno C., Alyami M., Bakrin N., Guiral D.C., Ceelen W., Delgadillo X., Dellinger T., Di Giorgio A., Kefleyesus A., et al. Consensus Statement for Treatment Protocols in Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Pleura Peritoneum. 2022;7:1–7. doi: 10.1515/pp-2022-0102. PubMed DOI PMC

Shree V., Lim T.J., Lean L.L., So B.Y.J., Kim G. Anaesthesia Considerations and Techniques for Pressurised IntraPeritoneal Aerosol Chemotherapy (PIPAC) Pleura Peritoneum. 2020;5:20190013. doi: 10.1515/pp-2019-0013. PubMed DOI PMC

Roensholdt S., Detlefsen S., Mortensen M., Graversen M. Response Evaluation in Patients with Peritoneal Metastasis Treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) J. Clin. Med. 2023;12:1289. doi: 10.3390/jcm12041289. PubMed DOI PMC

Hoskovec D., Varga J., Konečná E., Antoš F. Levels of CEA and Ca 19-9 in the Sera and Peritoneal Cavity in Patients with Gastric and Pancreatic Cancers. Acta Cir. Bras. 2012;27:410–416. doi: 10.1590/S0102-86502012000600009. PubMed DOI

Hoskovec D., Varga J., Dytrych P., Konecna E., Matek J. Peritoneal Lavage Examination as a Prognostic Tool in Cases of Gastric Cancer. Aoms. 2017;3:612–616. doi: 10.5114/aoms.2016.64044. PubMed DOI PMC

Ellebæk S.B., Graversen M., Detlefsen S., Lundell L., Fristrup C.W., Pfeiffer P., Mortensen M.B. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) of Peritoneal Metastasis from Gastric Cancer: A Descriptive Cohort Study. Clin. Exp. Metastasis. 2020;37:325–332. doi: 10.1007/s10585-020-10023-5. PubMed DOI

Balmer A., Clerc D., Toussaint L., Sgarbura O., Taïbi A., Hübner M., Teixeira Farinha H. Selection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases. Cancers. 2022;14:2557. doi: 10.3390/cancers14102557. PubMed DOI PMC

Ceribelli C., Debs T., Chevallier A., Piche M.A., Bereder J.M. Initial Experience of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in a French Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Expert Center. Surg. Endosc. 2020;34:2803–2806. doi: 10.1007/s00464-020-07488-6. PubMed DOI

Girshally R., Demtröder C., Albayrak N., Zieren J., Tempfer C., Reymond M.A. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) as a Neoadjuvant Therapy before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. World J. Surg. Oncol. 2016;14:253. doi: 10.1186/s12957-016-1008-0. PubMed DOI PMC

Sullivan K.M., Raoof M. Evaluating End Points of the Efficacy of Intraperitoneal Chemotherapy Techniques Including PIPAC. Ann. Surg. Oncol. 2023;30:2578–2581. doi: 10.1245/s10434-023-13124-z. PubMed DOI

Ezanno A.-C., Malgras B., Pocard M. Pressurized Intraperitoneal Aerosol Chemotherapy, Reasons for Interrupting Treatment: A Systematic Review of the Literature. Pleura Peritoneum. 2023;8:45–53. doi: 10.1515/pp-2023-0004. PubMed DOI PMC

Jansen-Winkeln B., Eberth J., Moulla Y., Mehdorn M., Niebisch S., Schierle K., Bläker H., Lordick F., Gockel I., Thieme R. Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Peritoneal Surface Malignancies (PSM): A Prospective Single-Center Registry Study. J. Cancer Res. Clin. Oncol. 2023;149:1331–1341. doi: 10.1007/s00432-022-04517-w. PubMed DOI PMC